litlas
Log inCreate account

Eva Ciruelos

Active 2008–2026

125
Papers
22,221
Citations
56
h-index
116
i10-index

Citations

Citations per year for Eva Ciruelos1993: 3 citations1999: 1 citations2001: 2 citations2003: 1 citations2009: 6 citations2010: 29 citations2011: 29 citations2012: 38 citations2013: 48 citations2014: 72 citations2015: 132 citations2016: 142 citations2017: 126 citations2018: 157 citations2019: 619 citations2020: 883 citations2021: 1,147 citations2022: 959 citations2023: 941 citations2024: 1,534 citations2025: 790 citations2026: 34 citations1994–1998: no citations, so these years are not shown2000: no citations, so this year is not shown2002: no citations, so this year is not shown2004–2008: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,245 citing papers, 20.5% of this breakdownChina: 1,089 citing papers, 9.9% of this breakdownItaly: 844 citing papers, 7.7% of this breakdownGermany: 581 citing papers, 5.3% of this breakdownUnited Kingdom: 547 citing papers, 5% of this breakdownSpain: 544 citing papers, 5% of this breakdownFrance: 480 citing papers, 4.4% of this breakdownSwitzerland: 377 citing papers, 3.4% of this breakdownCanada: 343 citing papers, 3.1% of this breakdownBelgium: 303 citing papers, 2.8% of this breakdownJapan: 295 citing papers, 2.7% of this breakdownAustralia: 269 citing papers, 2.5% of this breakdown
0%20.5%Other 27.7%

Institutions

Fields

  • Medicine59%
  • Biochemistry, Genetics and Molecular Biology35.1%
  • Immunology and Microbiology1.7%
  • Computer Science1.2%
  • Engineering0.7%
  • Chemistry0.4%
  • Other1.9%

Topics

  • HER2/EGFR in Cancer Research10%
  • Breast Cancer Treatment Studies9.1%
  • Advanced Breast Cancer Therapies8.4%
  • Cancer Treatment and Pharmacology3.7%
  • Cancer Genomics and Diagnostics3.5%
  • Cancer Immunotherapy and Biomarkers3%
  • Other62.3%

Coauthors

All papers

Open in search
  1. Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer

    Authors: Fabrice André, Eva Ciruelos, Gábor Rubovszky, Mario Campone, Sibylle Loibl, Hope S. Rugo, Hiroji Iwata, PierFranco Conte, Ingrid A. Mayer, Bella Kaufman, Toshinari Yamashita, Yen‐Shen Lu, Kenichi Inoue, Masato Takahashi, Zsuzsanna Pápai, Anne-Sophie Longin, David Mills, Celine Wilke, Samit Hirawat, Dejan Juric - New England Journal of Medicine 2019 cited by 2,572

  2. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

    Authors: Hope S. Rugo, Aditya Bardia, Frederik Marmé, Javier Cortés, Peter Schmid, Delphine Loirat, Olivier Trédan, Eva Ciruelos, Florence Dalenc, P. Gómez Pardo, Komal Jhaveri, Rosemary Delaney, T. Valdez, Hao Wang, Monica Motwani, Oh Kyu Yoon, Wendy Verret, Sara M. Tolaney - The Lancet 2023 cited by 427

  3. Spatial predictors of immunotherapy response in triple-negative breast cancer

    Authors: Xiao Qian Wang, Esther Danenberg, Chiun‐Sheng Huang, Daniel Egle, Maurizio Callari, Begoña Bermejo, Matteo Dugo, Claudio Zamagni, Marc Thill, Anton Anton, Stefania Zambelli, Stefania Russo, Eva Ciruelos, Richard Greil, Balázs Győrffy, Vladimir Semiglazov, Marco Colleoni, Catherine M. Kelly, Gabriella Mariani, Lucia Del Mastro, Olivia Biasi, Robert S. Seitz, Pinuccia Valagussa, Giuseppe Viale, Luca Gianni, Giampaolo Bianchini, H. Raza Ali - Nature 2023 cited by 325

  4. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

    Authors: Sandra M. Swain, David Miles, Sung‐Bae Kim, Young‐Hyuck Im, Seock‐Ah Im, Semiglazov Vf, Eva Ciruelos, Andreas Schneeweiß, Sherene Loi, Estefanía Monturus, Emma Clark, Adam Knott, Eleonora Restuccia, Mark Benyunes, Javier Cortés, Richy Agajanian, Rizvana Ahmad, Bahriye Aktas, Victor Hugo Medeiros Alencar, Dino Amadori, Jurandyr Moreira de Andrade, Fábio Franke, Catia Angiolini, Kenjiro Aogi, Jess F. Armor, Wichit Arpornwirat, L. Assersohn, William Audeh, Walter E. Aulitzky, Sérgio Jobim Azevedo, Maria Alejandra Bartoli, Norberto Batista López, María Inés Bianconi, Laura Biganzoli, Ruemu Birhiray, Marianna Bitiņa, Ron Blachy, Kimberly Blackwell, Rita A. Blanchard, Paulette Blanchet, Ion Boiangiu, B. Bower, Christine Brezden‐Masley, Adam Brufsky, Leanne S. Budde, Priscilla B. Caguioa, Lourdes Calvo, Mario Campone, Robert R. Carroll, Hugo R. Castro, Valorie F. Chan, Veena Charu, Saverio Cinieri, Michael Clemens, Emilio Alba Conejo, Eduardo Côrtes, Bruno Coudert, Eduardo Cronemberger, Daniel de Iracema Gomes Cubero, Shaker R. Dakhil, Brooke Daniel, Neville Davidson, Maria de Fátima Dias Gauí, Susana de la Cruz, María del Pilar, G. Delgado, John Ellerton, César Estuardo, Louis Fehrenbacher, Jean-­Marc Ferrero, Patrick J. Flynn, Małgorzata Foszczyńska‐Kłoda, Sandra Franco, Hirofumi Fujii, Chris Gallagher, Teresa Gamucci, N Giacomi, Miguel Gil Gil, Antonio González-Martı́n, Vera Gorbunova, E. Gotovkin, Nathan Green, Elza Grincuka, Eva‐Maria Grischke, Vincent Hansen, Jeffrey B. Hargis, Maik Hauschild, Roberto Hegg, Carolyn B. Hendricks, Róbert Hermann, Paulo M. Hoff, Jun Horiguchi, Javier Hornedo Muguiro, Stefano Iacobelli, Kenichi Inoue, Gustavo Ismael, Yoshinori Itoh, Dr Hiroji Iwata, D Jendiroba, Rosa Jochim and 122 more - The Lancet Oncology 2020 cited by 898

  5. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021

    Authors: Harold J. Burstein, Giuseppe Curigliano, Beat Thürlimann, William P. Weber, Philip Poortmans, Meredith M. Regan, H.-J. Senn, Eric P. Winer, Michael Gnant, Stephan Aebi, Fabrice André, Carlos Barrios, Jonas Bergh, Hervé Bonnefoi, Denisse Bretel Morales, Sara Y. Brucker, Harold J. Burstein, David Cameron, Fátima Cardoso, Lisa A. Carey, Boon Chua, Eva Ciruelos, Marco Colleoni, Giuseppe Curigliano, Suzette Delaloge, Carsten Denkert, Peter Dubsky, Bent Ejlertsen, Florian Fitzal, Prudence A. Francis, Viviana Galimberti, Hebatallah Gamal El Din Mohamed Mahmoud, Judy E. Garber, Michael Gnant, William J. Gradishar, Bahadır M. Güllüoğlu, Nadia Harbeck, Chiun‐Sheng Huang, Jens Huober, André Ilbawi, Zefei Jiang, Steven Johnston, Eun Sook Lee, Sibylle Loibl, Monica Morrow, Ann H. Partridge, Martine Piccart, Philip Poortmans, Aleix Prat, Meredith M. Regan, Isabella Rubio, Hope S. Rugo, Emiel J. Rutgers, Felix Sedlmayer, Vladimir Semiglazov, Hans-Joerg Senn, Zhiming Shao, Tanja Španić, Petra Tesařová, Beat Thürlimann, Sergei Tjulandin, Masakazu Toi, Maureen Trudeau, Nicholas Turner, Inez Vaz Luis, Giuseppe Viale, Toru Watanabe, William P. Weber, Eric P. Winer, Binghe Xu - Annals of Oncology 2021 cited by 803

  6. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

    Authors: Sandra M. Swain, José Baselga, Sung‐Bae Kim, Jungsil Ro, Vladimir Semiglazov, Mario Campone, Eva Ciruelos, Jean-­Marc Ferrero, Andreas Schneeweiß, Sarah Heeson, Emma Clark, Graham Ross, Mark Benyunes, Javier Cortés - New England Journal of Medicine 2015 cited by 2,139

  7. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1

    Authors: Fabrice André, Eva Ciruelos, Dejan Juric, Sibylle Loibl, Mario Campone, Ingrid A. Mayer, Gábor Rubovszky, Toshinari Yamashita, Bella Kaufman, Yen‐Shen Lu, Kenichi Inoue, Zsuzsanna Pápai, Masato Takahashi, Farhat Ghaznawi, David Mills, Mathilde Kaper, Michelle C. Miller, PierFranco Conte, Hiroji Iwata, Hope S. Rugo - Annals of Oncology 2020 cited by 599

  8. Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

    Authors: Hope S. Rugo, Aditya Bardia, Frederik Marmé, Javier Cortés, Peter Schmid, Delphine Loirat, Olivier Trédan, Eva Ciruelos, Florence Dalenc, P. Gómez Pardo, Komal Jhaveri, Rosemary Delaney, Olivia Fu, Lanjia Lin, Wendy Verret, Sara M. Tolaney - Journal of Clinical Oncology 2022 cited by 298

  9. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

    Authors: Hope S. Rugo, Florence Lerebours, Eva Ciruelos, Pamela Drullinsky, Manuel Ruíz‐Borrego, Patrick Neven, Yeon Hee Park, Aleix Prat, Thomas Bachelot, Dejan Juric, Nicholas C. Turner, Nickolas A. Sophos, Juan Pablo Zarate, Christina Arce, Yu-Ming Shen, Stuart Turner, Hemanth Kanakamedala, Wei‐Chun Hsu, Stephen Chia - The Lancet Oncology 2021 cited by 349

  10. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study

    Authors: Luca Gianni, Chiun‐Sheng Huang, Daniel Egle, Begoña Bermejo, C. Zamagni, Marc Thill, A. Antón, Stefania Zambelli, Giampaolo Bianchini, Salvatore Russo, Eva Ciruelos, Richard Greil, Semiglazov Vf, Marco Colleoni, Catherine M. Kelly, Gabriella Mariani, Lucia Del Mastro, I. Maffeis, Pinuccia Valagussa, Giuseppe Viale - Annals of Oncology 2022 cited by 386

  11. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

    Authors: Giuseppe Curigliano, Harold J. Burstein, Eric P. Winer, Michael Gnant, Peter Dubsky, Sibylle Loibl, Marco Colleoni, Meredith M. Regan, Martine Piccart, Hans-Jörg Senn, Beat Thürlimann, Fabrice André, José Baselga, Jonas Bergh, Hervé Bonnefoi, Sara Y. Brucker, Fátima Cardoso, Lisa A. Carey, Eva Ciruelos, Jack Cuzick, Carsten Denkert, Angelo Di Leo, Bent Ejlertsen, Prudence A. Francis, V.E. Galimberti, Judy E. Garber, Bahadır M. Güllüoğlu, Pamela J. Goodwin, Nadia Harbeck, Daniel F. Hayes, Chiun‐Sheng Huang, Jens Huober, Hussein Khaled, Jacek Jassem, Zefei Jiang, Per Karlsson, Monica Morrow, Roberto Orecchia, Kent C. Osborne, Olivia Pagani, Ann H. Partridge, K. Pritchard, Jungsil Ro, Emiel J. Rutgers, Felix Sedlmayer, Semiglazov Vf, Zhi‐Ming Shao, Ian Smith, Masakazu Toi, Andrew Tutt, Giuseppe Viale, Toru Watanabe, Timothy J. Whelan, Binghe Xu - Annals of Oncology 2017 cited by 1,255

  12. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

    Authors: Prudence A. Francis, Olivia Pagani, Gini F. Fleming, Barbara Walley, Marco Colleoni, István Láng, Henry Gómez, Carlo Tondini, Eva Ciruelos, Harold J. Burstein, Hervé Bonnefoi, Meritxell Bellet, Silvana Martino, Charles E. Geyer, Matthew P. Goetz, Vered Stearns, Graziella Pinotti, Fabio Puglisi, Simon Spazzapan, Miguel Ángel Climent, Lorenzo Pavesi, Thomas Ruhstaller, Nancy E. Davidson, Robert L. Coleman, Marc Debled, Stefan Buchholz, James N. Ingle, Eric P. Winer, Rudolf Maibach, Manuela Rabaglio, Barbara Ruepp, Angelo Di Leo, Alan S. Coates, Richard D. Gelber, Aron Goldhirsch, Meredith M. Regan - New England Journal of Medicine 2018 cited by 673

  13. Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials

    Authors: Olivia Pagani, Barbara Walley, Gini F. Fleming, Marco Colleoni, István Láng, Henry Gómez, Carlo Tondini, Harold J. Burstein, Matthew P. Goetz, Eva Ciruelos, Vered Stearns, Hervé Bonnefoi, Silvana Martino, Charles E. Geyer, Claudio Chini, Fabio Puglisi, Simon Spazzapan, Thomas Ruhstaller, Eric P. Winer, Barbara Ruepp, Sherene Loi, Alan S. Coates, Richard D. Gelber, Aron Goldhirsch, Meredith M. Regan, Prudence A. Francis - Journal of Clinical Oncology 2022 cited by 154

  14. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

    Authors: Luca Gianni, W. Eiermann, Semiglazov Vf, Alexey Manikhas, Aňa Lluch, S. Tjulandin, Milvia Zambetti, Federico Vázquez, Mikhail Byakhow, Mikhail Lichinitser, Miguel Ángel Climent, Eva Ciruelos, B. Ojeda, Mauro Mansutti, А. А. Божок, Roberta Baronio, A. Feyereislova, Claire Barton, Pinuccia Valagussa, José Baselga - The Lancet 2010 cited by 1,268

  15. Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative

    Authors: Philippe Aftimos, Mafalda Oliveira, Alexandre Irrthum, Debora Fumagalli, Christos Sotiriou, Einav Nili Gal‐Yam, Mark E. Robson, Justin Ndozeng, Angelo Di Leo, Eva Ciruelos, Evandro de Azambuja, Giuseppe Viale, Elsemieke D. Scheepers, Giuseppe Curigliano, Judith M. Bliss, Jorge S. Reis‐Filho, Marco Colleoni, Marija Balić, Fátima Cardoso, Joan Albanell, Caroline Duhem, Sandrine Marréaud, Dario Romagnoli, Beatriz Rojas, Andrea Gombos, Hans Wildiers, Ángel Guerrero‐Zotano, Peter S Hall, Andrea Bonetti, Karolina Larsson, Martina Degiorgis, Silvia Khodaverdi, Richard Greil, Ásgerður Sverrisdóttir, Marta Paoli, Ethel Seyll, Sibylle Loibl, Barbro Linderholm, Gabriele Zoppoli, Nancy E. Davidson, Oskar T. Johannsson, Philippe L. Bédard, Sherene Loi, Susan Knox, David Cameron, Nadia Harbeck, Maite Lasa Montoya, Mariana Brandão, Andrea Vingiani, Carmela Caballero, Florentine Hilbers, Lucy Yates, Matteo Benelli, David Venet, Martine Piccart - Cancer Discovery 2021 cited by 177

  16. Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

    Authors: Olivia Pagani, Meredith M. Regan, Barbara Walley, Gini F. Fleming, Marco Colleoni, István Láng, Henry Gómez, Carlo Tondini, Harold J. Burstein, Edith A. Perez, Eva Ciruelos, Vered Stearns, Hervé Bonnefoi, Silvana Martino, Charles E. Geyer, Graziella Pinotti, Fabio Puglisi, Diana Crivellari, Thomas Ruhstaller, Eric P. Winer, Manuela Rabaglio, Rudolf Maibach, Barbara Ruepp, Anita Giobbie‐Hurder, Karen N. Price, Jürg Bernhard, Weixiu Luo, Karin Ribi, Giuseppe Viale, Alan S. Coates, Richard D. Gelber, Aron Goldhirsch, Prudence A. Francis - New England Journal of Medicine 2014 cited by 747

  17. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer

    Authors: Hope S. Rugo, Fabrice André, Toshinari Yamashita, Humberto Cerda, I. Toledano, Salomon M. Stemmer, Josefina Cruz Jurado, Dejan Juric, Ingrid A. Mayer, Eva Ciruelos, Hiroji Iwata, PierFranco Conte, Mario Campone, C. Wilke, David Mills, Agnes Lteif, Michelle C. Miller, Fiorenza Gaudenzi, Sibylle Loibl - Annals of Oncology 2020 cited by 187

  18. Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

    Authors: Ana C. Garrido-Castro, Cristina Saura, Romualdo Barroso‐Sousa, Hao Guo, Eva Ciruelos, Begoña Bermejo, Joaquín Gavilá, Violeta Serra, Aleix Prat, Laia Paré, P. Céliz, Patricia Villagrasa, Yisheng Li, Jennifer Savoie, Zhan Xu, Carlos L. Arteaga, Ian E. Krop, David B. Solit, Gordon B. Mills, Lewis C. Cantley, Eric P. Winer, Nancy U. Lin, Jordi Rodón - Breast Cancer Research 2020 cited by 146

  19. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial

    Authors: Aleix Prat, Cristina Saura, Tomás Pascual, Cristina Hernándo, Montserrat Muñoz-Mateu, Laia Paré, Blanca González‐Farré, Pedro L. Fernández, Patricia Galván, Núria Chic, Xavier González, Mafalda Oliveira, Miguel Gil‐Gil, Míriam Arumí, Neus Ferrer, Álvaro Montaño, Yann Izarzugaza, Antonio Llombart‐Cussac, Raquel Bratos, Santiago González Santiago, Eduardo Martínez de Dueñas, Sergio Hoyos, Beatriz Rojas, Juan Antonio Virizuela, Vanesa Ortega, Rafael López‐López, P. Céliz, Eva Ciruelos, Patricia Villagrasa, Joaquín Gavilá - The Lancet Oncology 2019 cited by 201

  20. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial

    Authors: Nadia Harbeck, Eva Ciruelos, Guy Jérusalem, Volkmar Müller, Naoki Niikura, Giuseppe Viale, Rupert Bartsch, Christian Kurzeder, Michaela J. Higgins, Roisín M. Connolly, Sally Baron‐Hay, María Gión, Valentina Guarneri, Giampaolo Bianchini, Hans Wildiers, Santiago Escrivá-de-Romaní, Manoj Prahladan, Helen Bridge, Nataliya Kuptsova‐Clarkson, Nana Scotto, Sunil Verma, Nancy U. Lin, the DESTINY-Breast12 study group, Belinda Yeo, Nicole McCarthy, Amelia McCartney, Timothy Clay, Nicholas Murray, Andrea Gombos, Joëlle Collignon, Eveline De Cuypere, Katarzyna Jerzak, Stephen Chia, Maja Maraldo, Jeanette Rønlev, Eva Brix, Minna Tanner, Johanna Mattson, Riikka Huovinen, Pauline Wimberger, Mattea Reinisch, Hans Tesch, Michael Untch, Peter Fasching, Tjoung-Won Park-Simon, Joke Tio, Michael Braun, Eva Maria Grischke, Frederik Marmé, Marion van Mackelenbergh, John McCaffrey, Michelino De Laurentiis, Michele Caruso, Rossana Berardi, Laura Biganzoli, Vittoria Fotia, Toshinari Yamashita, Junji Tsurutani, Koichiro Tsugawa, Nobumoto Tomioka, Maaike de Boer, Daniel Houtsma, Martin Pilskog, Olav Engebråten, Anna Sætersdal, Piotr Wysocki, Zbigniew Nowecki, Barbara Radecka, Jacek Jassem, Renata Duchnowska, Joana Simões, Fatima Cardoso, Ana Rita Sousa, María Jesús Vidal Losada, Cristina Saura Manich, Joaquin Gavilá Gregori, Maria Pilar Lopez Marti, Manuel Ruiz Borrego, Javier Cortés Castán, Rafael López López, César Rodríguez Sanchez, Encarnación González Flores, Carmen Hinojo González, Purificación Martínez del Prado, Aglaia Schiza, Fredrika Killander, Leif Klint, Lorenzo Rossi, Stefan Aebi, Khalil Zaman, Peter Hall, Carey Anders - Nature Medicine 2024 cited by 183

  21. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: Angelo Di Leo, Stephen Johnston, Keun Seok Lee, Eva Ciruelos, Per Eystein Lønning, Wolfgang Janni, Ruth O’Regan, Marie‐Ange Mouret‐Reynier, Dimitar Kalev, Daniel Egle, Tibor Csőszi, Roberto Bordonaro, Thomas Decker, Vivianne C. G. Tjan‐Heijnen, Sibel Blau, Alessio Schirone, Denis Weber, Mona El-Hashimy, Bharani Dharan, Dalila Sellami, Thomas Bachelot - The Lancet Oncology 2017 cited by 381

  22. Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial

    Authors: Eva Ciruelos, Patricia Villagrasa, Tomás Pascual, Mafalda Oliveira, Sònia Pernas, Laia Paré, Santiago Escrivá-de-Romaní, Luís Manso, Bárbara Adamo, Eduardo Martínez de Dueñas, Javier Cortés, Silvia Vázquez, Antonia Perelló, Isabel Garau, Mireia Melé, Noelia Martínez, Álvaro Montaño, Begoña Bermejo, Serafín Morales, María José Echarri, Estela Vega, Blanca González‐Farré, Eduardo Martínez de Dueñas, Patricia Galván, Jordi Canes, Paolo Nucíforo, Xavier González, Aleix Prat - Clinical Cancer Research 2020 cited by 113

  23. Adjuvant Ovarian Suppression in Premenopausal Breast Cancer

    Authors: Prudence A. Francis, Meredith M. Regan, Gini F. Fleming, István Láng, Eva Ciruelos, Meritxell Bellet, Hervé Bonnefoi, Miguel Ángel Climent, Gian Antonio Da Prada, Harold J. Burstein, Silvana Martino, Nancy E. Davidson, Charles E. Geyer, Barbara Walley, Robert E. Coleman, Pierre Kerbrat, Stefan Buchholz, James N. Ingle, Eric P. Winer, Manuela Rabaglio, Rudolf Maibach, Barbara Ruepp, Anita Giobbie‐Hurder, Karen N. Price, Marco Colleoni, Giuseppe Viale, Alan S. Coates, Aron Goldhirsch, Richard D. Gelber - New England Journal of Medicine 2014 cited by 727

  24. A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results

    Authors: E. Hamilton, Maila Dayane Capuchinho de Oliveira, Nicholas C. Turner, J. García-Corbacho, Cristina Hernándo, Eva Ciruelos, Peter Kabos, Manuel Ruíz‐Borrego, Anne Armstrong, Mehul Patel, Christos Vaklavas, Chris Twelves, Valentina Boni, Jason Incorvati, Tim Brier, L. Gibbons, Teresa Klinowska, Justin P.O. Lindemann, Christopher J. Morrow, Anne-Marie Sykes, Richard D. Baird - Annals of Oncology 2024 cited by 62